Codexis (NASDAQ:CDXS) Bolsa

CODEXIS INC

Codexis

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Inc

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Management to host conference call today at 8 am Eastern Time to discuss data
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demonstrating the potential to control stereochemistry. In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis' ligation processes to their in-house facilities.

News

CDXS

Codexis Presents Data At TIDES USA Showcasing Proprietary ECO Synthesis Platform's Ability To Support siRNA Manufacturing By Reducing Purification Costs, Improving Process Performance, And Demonstrating Potential To Control Stereochemistry

WIIM

Codexis shares are trading lower after the company reported worse-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock moved upwards by 202.1% to $0.1 during Wednesday's after-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock moved upwards by 53.33% to $2.07. The company's market cap stands at $12.7 million. As per the news, the Q3 earnings report came out today. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 30.21% to $4.87. The company's market cap stands at $13.3 million. As per the press release, Q1 earnings came out today. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock increased by 21.46% to $5.96. The company's market cap stands at $53.6 million. The company's, Q1 earnings came out today. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock moved upwards by 19.23% to $0.23. The company's market cap stands at $9.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares moved upwards by 15.69% to $0.33. The company's market cap stands at $9.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock declined by 11.3% to $0.09 during Wednesday's after-market session. The market value of their outstanding shares is at $1.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) stock declined by 8.97% to $0.96. The market value of their outstanding shares is at $5.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) stock decreased by 7.25% to $0.87. The market value of their outstanding shares is at $8.1 million. As per the news, the Q2 earnings report came out today. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock declined by 6.99% to $0.21. The market value of their outstanding shares is at $2.0 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock decreased by 6.95% to $3.35. The company's market cap stands at $35.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares decreased by 6.48% to $2.31. The company's market cap stands at $191.3 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AVTX

AXDX

AYTU

BNGO

CARM

CHRO

CTXR

ICCC

KLTO

ONCO

TNFA

12 Health Care Stocks Moving In Wednesday's After-Market Session

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) affirms FY2025 sales outlook from $64.00 million-$68.00 million to $64.00 million-$68.00 million vs $65.67 million estimate.

Guidance

Codexis Affirms FY2025 Sales Guidance of $64.00M-$68.00M vs $65.67M Est

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $7.54 million which missed the analyst consensus estimate of $9.66 million by 21.93 percent. This is a 55.82 percent decrease over sales of $17.07 million the same period last year.

Earnings

Earnings Misses

Codexis Q1 EPS $(0.25) Misses $(0.23) Estimate, Sales $7.54M Miss $9.66M Estimate

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

BCDA

BITF

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BRTX

BZAI

CAAS

CANG

CCAP

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

CTSO

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Codexis will report an earnings per share (EPS) of $-0.20.
Anticipation surrounds Codexis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.11, leading to a 22.65% drop in the share price on the subsequent day.
Here's a look at Codexis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.24</td>
<td>-0.27</td>
<td>-0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.29</td>
<td>-0.32</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-23.0%</td>
<td>11.0%</td>
<td>-11.0%</td>
<td>17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747170191_0.png" alt="eps graph" />
<h3>Performance of Codexis Shares</h3>
Shares of Codexis were trading at $2.64 as of May 12. Over the last 52-week period, shares are down 30.41%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CDXS/earnings">To track all earnings releases for Codexis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Codexis's Earnings

Codexis shares are trading higher after the company announced it secured its first revenue deal for ECO Synthesis.

<ul>
<li>Represents first project to enter the ECO Synthesis&#x2122; Innovation Lab
<ul>
<li>Core enzymes for ECO Synthesis&#x2122; technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain</li>
</ul>
</li>
</ul>

Codexis Secures First Revenue Deal For ECO Synthesis, Marks Milestone In Enzymatic siRNA Manufacturing

Codexis shares are trading lower after the company reported worse-than-expected Q4 financial results.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) sees FY2025 sales of $64.000 million-$68.000 million vs $66.61 million analyst estimate.

Codexis Sees FY2025 Sales $64.000M-$68.000M vs $66.61M Est

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.04) by 225 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $21.46 million which missed the analyst consensus estimate of $27.41 million by 21.71 percent. This is a 19.20 percent decrease over sales of $26.56 million the same period last year.

Codexis Q4 EPS $(0.13) Misses $(0.04) Estimate, Sales $21.46M Miss $27.41M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.0, with a high estimate of $11.00 and a low estimate of $11.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1732287644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Codexis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Codexis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Codexis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Codexis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CDXS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Codexis analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Codexis: A Closer Look</h2>
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
<h3>Financial Insights: Codexis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Codexis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 38.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -160.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Codexis's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Codexis's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.73%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Codexis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)

Cantor Fitzgerald analyst Kristen Kluska reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight and maintains $11 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform and establish Codexis' position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.

Biotech

General

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

Comments

Codexis

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL